Clinical Trial: NCT03417544
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Nancy Lin, MD |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-08-21 |
Study Overview
Brief Summary
This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain.
The names of the study drugs involved in this study are:
- Atezolizumab
- Pertuzumab
- Trastuzumab
Official Title
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer
Conditions
HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
Intervention / Treatment
- Drug: ATEZOLIZUMAB
- Drug: PERTUZUMAB
- Drug: TRASTUZUMAB
Other Study ID Numbers
- 17-546
Start Date (Actual)
2018-05-21
Primary Completion Date (Actual)
2020-05-20
Study Completion Date (Actual)
2026-04-17
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Nancy Lin, MD |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-08-21 |
Study Overview
Brief Summary
This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain.
The names of the study drugs involved in this study are:
- Atezolizumab
- Pertuzumab
- Trastuzumab
Official Title
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer
Conditions
HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
Intervention / Treatment
- Drug: ATEZOLIZUMAB
- Drug: PERTUZUMAB
- Drug: TRASTUZUMAB
Other Study ID Numbers
- 17-546
Start Date (Actual)
2018-05-21
Primary Completion Date (Actual)
2020-05-20
Study Completion Date (Actual)
2026-04-17
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 2